ArticleEJHaem2025
Moderate-Severe Thrombocytopenia Portends Poor Outcomes in Multiple Myeloma.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Routine Laboratory-Based Machine Learning for Discriminating Multiple Myeloma from Clinical Mimickers: Development and Internal Validation of a Diagnostic Prediction Model.Diagnostics (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Malignant plasma cells in multiple myeloma (MM) reprogram the bone marrow microenvironment to support tumor expansion. This myeloma cell-hematopoietic stem cell interaction leads to fewer hematopoietic stem cells in the bone marrow and altered differentiation of megakaryocytes, which can contribute to MM disease-related thrombocytopenia. Given the development of novel therapies for MM and the need for biomarkers reflecting the bone marrow microenvironment, we evaluated peripheral blood platelet count at diagnosis and during treatment of MM. Methods: We retrospectively evaluated 14,313 patients diagnosed with MM between 2000 and 2019 at Veterans Administration hospitals using platelet count obtained closest to diagnosis and up to 2.5 years thereafter. Patients were stratified into four categories: moderate-severe thrombocytopenia, mild thrombocytopenia, normal platelets, and thrombocytosis (< 100, 100-149, 150-349, and ≥ 350 per microliter, respectively). Results: Thrombocytopenia, present in 25% of patients at diagnosis, corresponded to inferior overall survival (OS). During follow-up, persistent or new thrombocytopenia was also associated with inferior OS. Moreover, the negative prognostication afforded by baseline moderate-severe thrombocytopenia remained despite standard therapies (hazard ratio [HR] 1.83; 95% confidence interval [CI] 1.70-1.97) and stem cell transplant (HR 1.41; 95% CI 1.34-1.48). Conclusion: Our findings support the use of platelet count in MM as an easily accessible prognostic marker. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.